Radiation therapy for metastatic gastrointestinal cancers
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding radiation therapy to your current immunotherapy can help control cancer that has spread in the digestive system. It aims to improve symptoms and possibly slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a gastrointestinal cancer that has spread, such as cancer of the esophagus, stomach, liver, pancreas, or colon.
- You are currently receiving immunotherapy and your cancer has continued to grow despite it.
- You have between 1 and 5 areas of cancer that need radiation to relieve symptoms like pain, bleeding, or trouble swallowing.
- You must be able to receive both radiation and immunotherapy as decided by your doctors.
- You are at least 18 years old and expected to live more than 6 months.
- You are generally able to care for yourself (ECOG 0-2 or Karnofsky 50 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of short-course radiation, standard chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with advanced or metastatic gastric cancer that hasn't spread to lymph nodes. The goal is to see if this approach can help shrink or control the tumor.
This trial tests whether adding radiotherapy can help people with metastatic esophageal cancer that has already responded well to initial treatment with immunotherapy and chemotherapy. It may offer a way to improve outcomes for those whose cancer has not progressed after 2-4 cycles of first-line treatment.
This trial tests combining immunotherapy with radiation for a specific type of stomach or esophagus cancer that has a genetic marker called dMMR/MSI-H. It aims to see if this combination can help people who haven't had any prior treatment.
This trial tests if adding a probiotic (Lactobacillus rhamnosus M9) to standard radiation and immunotherapy can help people with advanced digestive system cancers. It aims to see if the combination is more effective and safer than the standard approach alone.
This trial tests whether adding radiation to a combination of chemotherapy and immunotherapy can help people with stage IV esophageal cancer that has spread. It is for those who haven't had any prior treatment for their cancer.
This trial combines a special high-dose radiation (SBRT) with immunotherapy to treat esophageal cancer that has spread to a few spots in the body (up to 5 spots in up to 3 organs). The goal is to see if this approach can better control the cancer.
Hear when a new Metastatic Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.